U
LJPC

UBS’s La Jolla Pharmaceutical Company LJPC Stock Holding History

UBS’s Portfolio LJPC Stock Details LJPC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		$27K Sell
2,800
-700
-20% -$6.97K ﹤0.01% 7646
2014
Q2 		$32K Buy
3,500
+3,412
+3,877% +$31.1K ﹤0.01% 7494
2014
Q1 		$1K Buy
+88
New +$863 ﹤0.01% 10352

Other funds holding LJPC

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BGA
Belmont Global Advisors Dallas, Texas $106M AUM 2.89% 1-Year Est. Return

UBS's LJPC Position: Q3 2014 in Review

UBS reduced its La Jolla Pharmaceutical Company (LJPC) stake by 20% in Q3 2014, selling an estimated $6.97K and leaving 2,800 shares worth $27K. The position accounts for ﹤0.01% of the portfolio, ranked #7646.

UBS first reported a position in LJPC in Q1 2014 and has held it in 3 quarters since. The position peaked at $32K in Q2 2014. 29 funds tracked by Wall St. Rank hold LJPC as of Q3 2014.

  • UBS held 2,800 shares of La Jolla Pharmaceutical Company worth $27K as of Q3 2014.
  • UBS sold 700 La Jolla Pharmaceutical Company shares in Q3 2014, an estimated $6.97K.
  • La Jolla Pharmaceutical Company made up ﹤0.01% of UBS's portfolio in Q3 2014, its #7646 holding.
  • UBS first reported a position in La Jolla Pharmaceutical Company in Q1 2014 and has held it in 3 quarters since.
  • UBS's La Jolla Pharmaceutical Company position peaked at $32K in Q2 2014.
  • 29 funds tracked by Wall St. Rank held La Jolla Pharmaceutical Company as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.